Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05201430
Other study ID # 2108240-5
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 27, 2021
Est. completion date July 2027

Study information

Verified date February 2022
Source Fudan University
Contact Tianan Guo
Phone +86-021-64035387
Email 11307120071@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date July 2027
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - MRI evaluated of T3-4 or N+ rectal cancer; - Pathologically diagnosed of rectal adenocarcinoma; - 18 to 75 years old; - Distance from lower margin of tumor to anus <15 cm and suitable for anus-preserving resection; - Tumor amenable to radical resection; - Treatment-na?ve patients with no previous systemic chemotherapy, radiotherapy or local excision for treating rectal cancer; - Laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count = 1.5×10^9/L, Platelet count = 100×10^9 /L, Hemoglobin = 80 g/L, Serum bilirubin = 24umol/L, Alanine aminotransferase and aspartate aminotransferase = 60 U/L, Serum creatinine = 110 umol/L; - Be capable to receive a surgery; - No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer; - No previous systemic chemotherapy for treating colorectal cancer; - Life expectancy of more than 3 months; - No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception; - Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1; - Be willing and able to understand the study and to provide written informed consent. Exclusion Criteria: - End-stage cachexia patients; - Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate chemotherapy or surgery; - Metastatic carcinoma; - Incomplete or complete intestinal obstruction; - Known to be allergic to capecitabine, 5-Fu, oxaliplatin or irinotecan; - Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures; - Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric historysevere infection; active disseminated intravascular coagulation; active hepatitis, severe coagulation disorder patients; - History of other malignancy within the past 5 years except effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer; - Serious organic disease including but not limited to heart, kidney, brain, and lung.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOXIRI
irinotecan* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
CapeOX
oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)

Locations

Country Name City State
China Department of Colorectal Surgery Fudan University Shanghai Caner Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year disease free survival Defined as the length of time from the date of randomization until the first documented date of progression or death from any cause, whichever comes first. Compare 3-year disease free survival in patients with locally advanced rectal cancer treated with either FOLFOXIRI or CapeOX neoadjuvant chemotherapy. 3 years
Secondary pathologic complete response rate Defined as the ratio of patients with pathologic TRG 0 1 year
Secondary major pathologic response rate Defined as the ratio of patients with pathologic TRG 0 or 1 1 year
Secondary objective response rate Defined as the ratio of patients with MRI-TRG 1, 2 or 3 1 year
Secondary local recurrence rate Defined as the ratio of patients with local recurrence within 3 years. 3 years
Secondary overall survival Defined as the length of time from randomization date until the date of death from any cause. 5 years
Secondary quality of life as assessed by EORTC QOL-C30 Quality of life after neoadjuvant chemotherapy is assessed by questionaires EORTC QOL-C30 version 3 3 years
Secondary quality of life as assessed by EORTC QOL-CR29 Quality of life after neoadjuvant chemotherapy is assessed by questionaires EORTC QOL-CR29. 3 years
Secondary adverse event Number of patients with adverse events and severity according to NCI CTC 5.0 after neoadjuvant chemotherapy. 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Active, not recruiting NCT02438839 - Curative Chemoradiation of Low Rectal Cancer